iCAD, Inc. (NASDAQ:ICAD) Sees Significant Growth in Short Interest

iCAD, Inc. (NASDAQ:ICAD) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 249,100 shares, a growth of 5.7% from the October 15th total of 235,600 shares. Approximately 1.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 171,900 shares, the short-interest ratio is presently 1.4 days.

Analysts Set New Price Targets

Separately, StockNews.com cut iCAD from a “hold” rating to a “sell” rating in a research note on Wednesday, November 13th.

Institutional Trading of iCAD

Several large investors have recently modified their holdings of the business. Virtu Financial LLC boosted its position in iCAD by 55.6% during the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after acquiring an additional 7,604 shares in the last quarter. Perritt Capital Management Inc boosted its position in iCAD by 14.2% during the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock valued at $208,000 after acquiring an additional 19,917 shares in the last quarter. Essex LLC bought a new stake in iCAD during the 3rd quarter valued at approximately $216,000. Finally, Perritt Capital Management Inc. boosted its position in iCAD by 7.5% during the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock valued at $225,000 after acquiring an additional 9,717 shares in the last quarter. 24.61% of the stock is owned by institutional investors.

iCAD Stock Performance

Shares of NASDAQ ICAD traded up $0.12 during trading hours on Tuesday, hitting $1.64. The company’s stock had a trading volume of 214,995 shares, compared to its average volume of 173,729. The stock has a market cap of $43.53 million, a price-to-earnings ratio of -12.03 and a beta of 1.47. iCAD has a 12 month low of $1.18 and a 12 month high of $2.65. The business has a 50-day simple moving average of $1.71 and a 200-day simple moving average of $1.54.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.